Bolt Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BOLT Nasdaq 2834 www.boltbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Aug 11th, 2026 3:45 pm
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 11th, 2026 2:05 pm
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project - Jun 12th, 2026 5:00 am
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight - Jun 1st, 2026 11:00 am
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 3:40 pm
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 2:05 pm
Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary - Apr 9th, 2026 1:00 am
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates - Mar 12th, 2026 3:45 pm
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - Mar 12th, 2026 2:05 pm
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates - Nov 12th, 2025 3:25 pm
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? - Nov 4th, 2025 8:00 am
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - Oct 1st, 2025 2:05 pm